In one paragraphArticle in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Nouha Setti BoubakerUOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0001-8342-6936 Aymone GurtnerUOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-7661-9059 Sami BoussettaLaboratory of Genetics, Immunology and Human Pathology, Biology Department, Faculty of Science of Tunis, University of Tunis El Manar, Tunis 2092, Tunisia.ORCID 0000-0003-3994-6701 Isabella ManniUOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0003-4823-0596 Ahmed SaadiUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia.ORCID 0000-0002-5361-9005 Haroun AyedUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia.ORCID 0000-0002-7365-0309 Livia RonchettiUOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-2367-3852 Ahlem BlelPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia.ORCID 0000-0001-6702-3889 Marouene ChakrounUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia.ORCID 0000-0002-0385-2917 Seif MokademUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia.ORCID 0000-0002-9226-610X Zeineb NaimiMedical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia.ORCID 0000-0002-9511-5403 Mohamed Ali BedouiUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia.ORCID 0000-0003-2919-1173 Linda Bel Haj KacemPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia.ORCID 0000-0002-1492-9799 Khedija MeddebMedical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia.ORCID 0000-0002-3418-1749 Soumaya RammehPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis 1006, Tunisia.ORCID 0000-0003-0366-4630 Mohamed Riadh Ben SlamaUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis 1006, Tunisia.
Slah OuerhaniLaboratory of Proteins Engineering and Bioactive Molecules (LIP-MB), Biology Engineering Department, National Institute of Applied Sciences and Technology (INSAT), University of Tunis Carthage, Tunis 1080, Tunisia.ORCID 0000-0002-3651-4690 Giulia PiaggioUOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0003-2114-1892 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundDespite clinical and pathological risk tools, predicting outcomes in non-muscle-invasive bladder cancer (NMIBC), particularly high-grade (HG) cases, remains challenging due to its unpredictable recurrence and progression. There is an urgent need for molecular biomarkers to enhance risk stratification and guide treatment.
methodsWe assessed the prognostic potential of eight miRNAs (miR-9, miR-143, miR-182, miR-205, miR-27a, miR-369, let-7c, and let-7g) in a cohort of ninety patients with primary bladder cancer. Expression data were retrieved from our previously published studies. Kaplan-Meier's and Cox's regression analyses were used to evaluate the associations with overall survival (OS), metastasis-free survival (MFS), and clinical outcomes. Principal component analysis (PCA) was performed to identify informative miRNA combinations. Target gene prediction, pathway enrichment (DAVID), and drug-gene interaction mapping (DGIdb) were conducted in silico.
resultsA high expression of let-7g and miR-9 was significantly associated with better OS in HG NMIBC and MIBC, respectively (
conclusionsLet-7g, miR-9, miR-143, miR-182, and miR-205 emerged as promising biomarkers for outcome prediction in NMIBC. Their integration into liquid biopsy platforms could support non-invasive monitoring and personalized treatment strategies. These findings warrant validation in larger, prospective studies and through functional assays.
Indexed as
biomarkerbladder cancerdrug interactionmicroRNApathway enrichmentprognosis
Identifiers
PMID40940866
PMCPMC12427307
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390